Login / Register 
United States ($) USD
Austria (€) EUR
Belgium (€) EUR
Finland (€) EUR
France (€) EUR
Germany (€) EUR
Ireland (€) EUR
Japan (¥) JPY
Luxembourg (€) EUR
Netherlands (€) EUR
Switzerland (CHF) CHF
United Kingdom (£) GBP
- Clone
- W22041G (See other available formats)
- Regulatory Status
- RUO
- Other Names
- Cytotoxic T-CD152, CELIAC3, GSE, IDDM12
- Isotype
- Rat IgG2a, κ
- Ave. Rating
- Submit a Review
- Product Citations
- publications
-
Biotinylated recombinant human CTLA-4- Fc chimera (Cat. No. 786704) (black circles) binds to immobilized recombinant human B7-2/CD86-Fc chimera (Cat. No. 775604). Ultra-LEAF™ purified anti-human CD152 (CTLA-4) (clone W22041G) (purple squares) inhibits the binding in a dose-dependent manner, whereas the Ultra-LEAF™ purified rat IgG2a, κ isotype control (Cat. No. 400544) (gray triangles) does not have effect. This antibody blocks the binding of 0.15 µg/mL biotinylated human CTLA-Fc chimera to 1 µg/mL immobilized recombinant human B7-2/CD86-Fc chimera. ND50 range: 0.07 - 0.5 μg/mL. -
Recombinant human CTLA-4-Fc chimera (Cat. No. 591904) (black circles) inhibits the production of human IL-2 induced by human B7.1 (CD80)-Fc in Jurkat cells. Ultra-LEAF™ purified anti-human CD152 (CTLA-4) (clone W22041G) (purple squares) neutralizes the inhibition effect of recombinant human CTLA-4-Fc chimera (Cat. No. 591904) at 0.1 µg /mL on production of human IL-2 induced by human B7.1 (CD80)-Fc in Jurkat cells in a dose-dependent manner whereas the Ultra-LEAF™ purified rat IgG2a, κ isotype control (gray triangles) (Cat. No. 400544) does not have effect. ND50 range: 0.75 - 4 µg/mL.
| Cat # | Size | Price | Quantity Check Availability | Save | ||
|---|---|---|---|---|---|---|
| 638153 | 100 µg | 336€ | ||||
| 638154 | 1 mg | 852€ | ||||
Human cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is a member of the IgG superfamily. It encodes a 223 amino acid protein and possesses a single extracellular V domain, a transmembrane domain, and a cytoplasmic domain. CTLA-4 is ~30% homologous with CD28, and both bind to the same ligands (B7.1/CD80 and B7.2/CD86) although CTLA-4 binds with higher affinity than CD28. Parallel recognition of a specific MHC-peptide complex by the T-cell receptor and of CD80 or CD86 by the costimulatory receptor CD28 results in T-cell activation, cytokine production, proliferation, and differentiation. After T cell activation process and upregulation of CTLA-4, co-ligation of the TCR to MHC-peptide complex and CTLA-4 to its ligands results in cell cycle arrest and ends T cell activation. It has been suggested that the negative regulatory mechanism of CTLA-4 is mediated through trans-endocytosis of CD80 and CD86 (capture of ligands from opposing cells). The ligands are removed from the original cell and degraded inside of CTLA-4-expressing cells. As a result, the action of CD28 is impaired. Alternative splice variants of CTLA-4 have been described in mouse and human that have transcripts that skip exon 2 (ligand-binding domain) or exon 3 (transmembrane domain). The ligand independent CTLA-4 is expressed in mice, but not in humans, and soluble CTLA-4 (sCTLA-4) is expressed in mice and humans. CTLA-4 is constitutively expressed by Tregs, and they are an important source of sCTLA-4. It has been suggested that sCTLA-4 potentiates regulatory T cell function. High levels of sCTLA-4 in Tregs have been associated with type 1 diabetes (T1D) and other autoimmune diseases, such as Grave's disease and myasthenia gravis. Also, CTLA-4 has been linked with proliferation and survival of chronic lymphocytic leukemia. CTLA-4 is a target for therapeutic intervention; in fact, a monoclonal antibody against CTLA-4 (Ipilimumab) has been approved for the treatment of melanoma.
Product DetailsProduct Details
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Rat
- Immunogen
- Recombinant Human CTLA-4-Fc chimera
- Formulation
- 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
- Endotoxin Level
- Less than 0.01 EU/μg of the protein (less than 0.001 ng/μg of the protein) as determined by the LAL test
- Preparation
- The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
- Concentration
- The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
- Application
-
Block - Quality tested
- Recommended Usage
-
Each lot of this antibody is quality control tested by blocking the binding of 0.15 µg/mL recombinant biotinylated human CTLA-4-Fc (Cat. No. 786704) to immobilized 1 µg/mL recombinant human B7-2/CD86-Fc chimera (Cat. No. 775604). ND50 range: 0.07 - 0.5 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
Antigen Details
- Structure
- Homodimer
- Distribution
-
Activated T cells, CD4, CD8, and Tregs
- Function
- Inhibits T cell activation by reducing IL-2 production and IL-2R expression, also arresting T cells in G1 phase of the cell cycle; protects against the development of autoimmunity.
- Interaction
- Antigen presenting cells, B cells
- Ligand/Receptor
- CD80 (B7.1), CD86 (B7.2)
- Cell Type
- B cells, T cells, Tregs
- Biology Area
- Immunology, Inhibitory Molecules
- Molecular Family
- CD Molecules, Immune Checkpoint Receptors
- Antigen References
-
- Linsley PS, et al. 1991. J Exp Med. 174:561-9.
- Pentcheva-Hoang T, et al. 2004. Immunity. 2:401-13.
- Qureshi OS, et al. 2011. Science. 332:600-3.
- Gerold KD, et al. 2011. Diabetes. 60:1955-63.
- Ryden A, et al. 2012. Diabetes Metab Res Rev. 28:84-96.
- Mittal AK, et al. 2013. PloS One. 8:e70352.
- Ward FJ, et al. 2013. Eur J Immunol. 43:1274-85.
- Gene ID
- 1493 View all products for this Gene ID
- UniProt
- View information about CD152 on UniProt.org
Related Pages & Pathways
Pathways
Related FAQs
- Do you guarantee that your antibodies are totally pathogen free?
-
BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
- Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
-
No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
- Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
-
No, BioLegend does not test for pathogens in-house unless otherwise indicated. However, we can recommend an outside vendor to perform this testing as needed.
- Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
-
We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.
Compare Data Across All Formats
This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.
Follow Us